{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,20]],"date-time":"2026-02-20T22:12:24Z","timestamp":1771625544111,"version":"3.50.1"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2015,11,6]],"date-time":"2015-11-06T00:00:00Z","timestamp":1446768000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100001843","name":"Science and Engineering Research Board","doi-asserted-by":"publisher","award":["SERB- SB\/FT\/LS-147\/2012"],"award-info":[{"award-number":["SERB- SB\/FT\/LS-147\/2012"]}],"id":[{"id":"10.13039\/501100001843","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Chemother Pharmacol"],"published-print":{"date-parts":[[2015,12]]},"DOI":"10.1007\/s00280-015-2905-6","type":"journal-article","created":{"date-parts":[[2015,11,6]],"date-time":"2015-11-06T12:30:20Z","timestamp":1446813020000},"page":"1185-1189","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["A study to explore the correlation of ABCB1, ABCG2, OCT1 genetic polymorphisms and trough level concentration with imatinib mesylate-induced thrombocytopenia in chronic myeloid leukemia patients"],"prefix":"10.1007","volume":"76","author":[{"given":"Jose","family":"Francis","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Biswajit","family":"Dubashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rajan","family":"Sundaram","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Suresh Chandra","family":"Pradhan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adithan","family":"Chandrasekaran","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2015,11,6]]},"reference":[{"key":"2905_CR1","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1056\/NEJM200104053441401","volume":"344","author":"BJ Druker","year":"2001","unstructured":"Druker BJ, Talpaz M, Resta DJ et al (2001) Efficacy and safety of a specific inhibitor of the BCR\u2013ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 344:1031\u20131037","journal-title":"N Engl J Med"},{"key":"2905_CR2","doi-asserted-by":"crossref","first-page":"2430","DOI":"10.3109\/10428194.2012.694076","volume":"53","author":"KC Lakshmaiah","year":"2012","unstructured":"Lakshmaiah KC, Bhise R, Purohit S et al (2012) Chronic myeloid leukemia in children and adolescents: results of treatment with imatinib mesylate. Leuk Lymphoma 53:2430\u20132433","journal-title":"Leuk Lymphoma"},{"key":"2905_CR3","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1200\/JCO.2004.03.050","volume":"22","author":"B Peng","year":"2004","unstructured":"Peng B, Hayes M, Resta D et al (2004) Pharmacokinetics and pharmacodynamics of imatinib in a phase I trial with chronic myeloid leukemia patients. J Clin Oncol 22:935\u2013942","journal-title":"J Clin Oncol"},{"key":"2905_CR4","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1002\/ajh.23180","volume":"87","author":"EJ Jabbour","year":"2012","unstructured":"Jabbour EJ, Kantarjian H, Eliasson L et al (2012) Patient adherence to tyrosine kinase inhibitor therapy in chronic myeloid leukemia. Am J Hematol 87:687\u2013691","journal-title":"Am J Hematol"},{"key":"2905_CR5","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1146\/annurev-genom-090413-025419","volume":"15","author":"M Pirmohamed","year":"2014","unstructured":"Pirmohamed M (2014) Personalized pharmacogenomics: predicting efficacy and adverse drug reactions. Annu Rev Genomics Hum Genet 15:349\u2013370","journal-title":"Annu Rev Genomics Hum Genet"},{"key":"2905_CR6","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1111\/cge.12392","volume":"86","author":"JW Lee","year":"2014","unstructured":"Lee JW, Aminkeng F, Bhavsar AP et al (2014) The emerging era of pharmacogenomics: current successes, future potential, and challenges. Clin Genet 86:21\u201328","journal-title":"Clin Genet"},{"key":"2905_CR7","first-page":"181","volume":"54","author":"B Mladosievicova","year":"2007","unstructured":"Mladosievicova B, Carter A, Kristova V (2007) Genetic tests for predicting the toxicity and efficacy of anticancer chemotherapy. Neoplasma 54:181\u2013188","journal-title":"Neoplasma"},{"key":"2905_CR8","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.1200\/JCO.2004.07.173","volume":"22","author":"F Innocenti","year":"2004","unstructured":"Innocenti F, Undevia SD, Iyer L et al (2004) Genetic variants in the UDP-glucuronosyltransferase 1A1 gene predict the risk of severe neutropenia of irinotecan. J Clin Oncol 22:1382\u20131388","journal-title":"J Clin Oncol"},{"key":"2905_CR9","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1111\/j.1365-2125.2008.03248.x","volume":"66","author":"AF Hawwa","year":"2008","unstructured":"Hawwa AF, Millership JS, Collier PS et al (2008) Pharmacogenomic studies of the anticancer and immunosuppressive thiopurines mercaptopurine and azathioprine. Br J Clin Pharmacol 66:517\u2013528","journal-title":"Br J Clin Pharmacol"},{"key":"2905_CR10","doi-asserted-by":"crossref","first-page":"5496","DOI":"10.1158\/1078-0432.CCR-06-0320","volume":"12","author":"R Largillier","year":"2006","unstructured":"Largillier R, Etienne-Grimaldi MC, Formento JL et al (2006) Pharmacogenetics of capecitabine in advanced breast cancer patients. Clin Cancer Res 12:5496\u20135502","journal-title":"Clin Cancer Res"},{"key":"2905_CR11","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1007\/s10147-013-0562-5","volume":"19","author":"T Shibata","year":"2014","unstructured":"Shibata T, Minami Y, Mitsuma A et al (2014) Association between severe toxicity of nilotinib and UGT1A1 polymorphisms in Japanese patients with chronic myelogenous leukemia. Int J Clin Oncol 19:391\u2013396","journal-title":"Int J Clin Oncol"},{"key":"2905_CR12","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1038\/sj.bjc.6605591","volume":"102","author":"L Huang","year":"2010","unstructured":"Huang L, Baker KL, Chen M et al (2010) Pazopanib- induced hyperbilirubinemia is associated with Gilbert\u2019s syndrome UGT1A1 polymorphism. Br J Cancer 102:1371\u20131377","journal-title":"Br J Cancer"},{"key":"2905_CR13","first-page":"133","volume":"74","author":"M Tamura","year":"2012","unstructured":"Tamura M, Kondo M, Horio M et al (2012) Genetic polymorphisms of the adenosine triphosphate-binding cassette transporters (ABCG2, ABCB1) and gefitinib toxicity. Nagoya J Med Sci 74:133\u2013140","journal-title":"Nagoya J Med Sci"},{"key":"2905_CR14","doi-asserted-by":"crossref","first-page":"1633","DOI":"10.1038\/sj.bjc.6604355","volume":"98","author":"N Widmer","year":"2008","unstructured":"Widmer N, Decosterd LA, Leyvraz S et al (2008) Relationship of imatinib-free plasma levels and target genotype with efficacy and tolerability. Br J Cancer 98:1633\u20131640","journal-title":"Br J Cancer"},{"key":"2905_CR15","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1097\/FTD.0b013e318292b931","volume":"35","author":"DH Josephs","year":"2013","unstructured":"Josephs DH, Fisher DS, Spicer J et al (2013) Clinical pharmacokinetics of tyrosine kinase inhibitors: implications for therapeutic drug monitoring. Ther Drug Monit 35:562\u2013587","journal-title":"Ther Drug Monit"},{"key":"2905_CR16","doi-asserted-by":"crossref","first-page":"667","DOI":"10.2217\/pgs.13.222","volume":"15","author":"B Zu","year":"2014","unstructured":"Zu B, Li Y, Wang X et al (2014) MDR1 gene polymorphisms and imatinib response in chronic myeloid leukemia: a meta-analysis. Pharmacogenomics 15:667\u2013677","journal-title":"Pharmacogenomics"},{"key":"2905_CR17","doi-asserted-by":"crossref","first-page":"3739","DOI":"10.1182\/blood-2003-12-4276","volume":"104","author":"J Thomas","year":"2004","unstructured":"Thomas J, Wang L, Clark RE et al (2004) Active transport of imatinib into and out of cells: implications for drug resistance. Blood 104:3739\u20133745","journal-title":"Blood"},{"key":"2905_CR18","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1186\/gm206","volume":"2","author":"S Dulucq","year":"2010","unstructured":"Dulucq S, Krajinovic M (2010) The pharmacogenetics of imatinib. Genome Med 2:85","journal-title":"Genome Med"},{"key":"2905_CR19","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1038\/tpj.2014.7","volume":"14","author":"A Paolo Di","year":"2014","unstructured":"Di Paolo A, Polillo M, Capecchi M et al (2014) The c. 480C\u00a0>\u00a0G polymorphism of hOCT1 influences imatinib clearance in patients affected by chronic myeloid leukemia. Pharmacogenomics J 14:328\u2013335","journal-title":"Pharmacogenomics J"},{"key":"2905_CR20","doi-asserted-by":"crossref","first-page":"3496","DOI":"10.1182\/blood-2006-07-036012","volume":"109","author":"S Picard","year":"2007","unstructured":"Picard S, Titier K, Etienne G et al (2007) Trough imatinib plasma levels are associated with both cytogenetic and molecular responses to standard-dose imatinib in chronic myeloid leukemia. Blood 109:3496\u20133499","journal-title":"Blood"},{"key":"2905_CR21","first-page":"1067","volume":"3","author":"J Francis","year":"2014","unstructured":"Francis J, Dubashi B, Sundaram R et al (2014) A simple and rapid method for the quantification of Imatinib mesylate and desmethyl imatinib in human Plasma using LC\u2013MS\/MS and its application to routine Therapeutic drug monitoring. World J Pharma Res 3:1067\u20131075","journal-title":"World J Pharma Res"},{"key":"2905_CR22","unstructured":"Common Terminology Criteria for Adverse Events (CTCAE). http:\/\/evs.nci.nih.gov\/ftp1\/CTCAE\/CTCAE_4.03_2010-06-14_QuickReference_8.5\u00d711.pdf . Accessed 23 Aug 2013"},{"key":"2905_CR23","doi-asserted-by":"crossref","first-page":"30","DOI":"10.4103\/0976-500X.149141","volume":"6","author":"J Francis","year":"2015","unstructured":"Francis J, Palaniappan M, Dubashi B, Pradhan SC, Adithan C (2015) Adverse drug reactions of imatinib therapy in chronic myeloid leukemia patients: a single-center surveillance study. J Pharmacol Pharmacother 6:30\u201333","journal-title":"J Pharmacol Pharmacother"},{"key":"2905_CR24","doi-asserted-by":"crossref","first-page":"6343","DOI":"10.1007\/s11033-012-1456-8","volume":"39","author":"G Umamaheswaran","year":"2012","unstructured":"Umamaheswaran G, Krishna Kumar D, Kayathiri D et al (2012) Inter and intra-ethnic differences in the distribution of the molecular variants of TPMT, UGT1A1 and MDR1 genes in the South Indian population. Mol Biol Rep 39:6343\u20136351","journal-title":"Mol Biol Rep"},{"key":"2905_CR25","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1038\/leu.2009.88","volume":"23","author":"JE Cortes","year":"2009","unstructured":"Cortes JE, Egorin MJ, Guilhot F et al (2009) Pharmacokinetic\/pharmacodynamic correlation and blood-level testing in imatinib therapy for chronic myeloid leukemia. Leukemia 23:1537\u20131544","journal-title":"Leukemia"},{"key":"2905_CR26","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1097\/FTD.0b013e31823cdec9","volume":"34","author":"JF Teng","year":"2012","unstructured":"Teng JF, Mabasa VH, Ensom MH (2012) The role of therapeutic drug monitoring of imatinib in patients with chronic myeloid leukemia and metastatic or unresectable gastrointestinal stromal tumors. Ther Drug Monit 34:85\u201397","journal-title":"Ther Drug Monit"},{"key":"2905_CR27","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1016\/j.leukres.2014.03.023","volume":"38","author":"V Gotta","year":"2014","unstructured":"Gotta V, Bouchet S, Widmer N et al (2014) Large-scale imatinib dose-concentration-effect study in CML patients under routine care conditions. Leuk Res 38:764\u2013772","journal-title":"Leuk Res"},{"key":"2905_CR28","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.leukres.2008.07.015","volume":"33","author":"DL Forrest","year":"2009","unstructured":"Forrest DL, Trainor S, Brinkman RR et al (2009) Cytogenetic and molecular responses to standard-dose imatinib in chronic myeloid leukemia are correlated with Sokal risk scores and duration of therapy but not trough imatinib plasma levels. Leuk Res 33:271\u2013275","journal-title":"Leuk Res"},{"key":"2905_CR29","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1158\/1078-0432.CCR-10-2250","volume":"17","author":"K Eechoute","year":"2011","unstructured":"Eechoute K, Sparreboom A, Burger H et al (2011) Drug transporters and imatinib treatment: implications for clinical practice. Clin Cancer Res 17:406\u2013415","journal-title":"Clin Cancer Res"},{"key":"2905_CR30","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1038\/jhg.2010.98","volume":"55","author":"N Takahashi","year":"2010","unstructured":"Takahashi N, Miura M, Scott SA et al (2010) Influence of CYP3A5 and drug transporter polymorphisms on imatinib trough concentration and clinical response among patients with chronic phase chronic myeloid leukemia. J Hum Genet 55:731\u2013737","journal-title":"J Hum Genet"},{"key":"2905_CR31","doi-asserted-by":"crossref","first-page":"4022","DOI":"10.1182\/blood-2007-10-116475","volume":"111","author":"RA Larson","year":"2008","unstructured":"Larson RA, Druker BJ, Guilhot F et al (2008) Imatinib pharmacokinetics and its correlation with response and safety in chronic-phase chronic myeloid leukemia: a subanalysis of the IRIS study. Blood 111:4022\u20134028","journal-title":"Blood"},{"key":"2905_CR32","doi-asserted-by":"crossref","first-page":"224","DOI":"10.4103\/0971-5851.123752","volume":"34","author":"B Arora","year":"2013","unstructured":"Arora B, Gota V, Menon H et al (2013) Therapeutic drug monitoring for imatinib: current status and Indian experience. Indian J Med Paediatr Oncol 34:224\u2013228","journal-title":"Indian J Med Paediatr Oncol"},{"key":"2905_CR33","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1007\/s12185-009-0315-4","volume":"89","author":"T Kawaguchi","year":"2009","unstructured":"Kawaguchi T, Hamada A, Hirayama C et al (2009) Relationship between an effective dose of imatinib, body surface area, and trough drug levels in patients with chronic myeloid leukemia. Int J Hematol 89:642\u2013648","journal-title":"Int J Hematol"}],"container-title":["Cancer Chemotherapy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-015-2905-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00280-015-2905-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-015-2905-6","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,25]],"date-time":"2022-05-25T15:08:43Z","timestamp":1653491323000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00280-015-2905-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,11,6]]},"references-count":33,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2015,12]]}},"alternative-id":["2905"],"URL":"https:\/\/doi.org\/10.1007\/s00280-015-2905-6","relation":{},"ISSN":["0344-5704","1432-0843"],"issn-type":[{"value":"0344-5704","type":"print"},{"value":"1432-0843","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,11,6]]}}}